PMID- 30419348
OWN - NLM
STAT- MEDLINE
DCOM- 20191101
LR  - 20191101
IS  - 1872-7980 (Electronic)
IS  - 0304-3835 (Linking)
VI  - 442
DP  - 2019 Feb 1
TI  - Exosomes derived from human umbilical cord mesenchymal stromal cells deliver 
      exogenous miR-145-5p to inhibit pancreatic ductal adenocarcinoma progression.
PG  - 351-361
LID - S0304-3835(18)30660-8 [pii]
LID - 10.1016/j.canlet.2018.10.039 [doi]
AB  - The roles of miRNAs in the development of cancer have made them promising tools 
      for novel therapeutic approaches. However, the successful delivery of miRNAs to 
      cancer cells has been hampered by difficulties in developing an effective and 
      sustainable delivery mechanism. Exosomes are small endogenous membrane vesicles 
      that mediate communication between cells by delivering genetic materials. Thus, 
      given their intrinsic properties, exosomes have been a focus for use as 
      biological delivery vehicles for miRNAs transfer. Whether exosomes can 
      effectively deliver exogenous miRNAs to pancreatic ductal adenocarcinoma (PDAC) 
      cells has not been thoroughly investigated. Here, we used exosomes from human 
      umbilical cord mesenchymal stromal cells (hucMSCs) to deliver exogenous 
      miR-145-5p, which inhibited PDAC cell proliferation and invasion and increased 
      apoptosis and cell cycle arrest, concomitant with decreased Smad3 expression in 
      vitro. Using a mouse model, we also demonstrated that overexpressing miR-145-5p 
      significantly reduced the growth of xenograft tumors in vivo. Our findings 
      provide novel insights that exosomes might be an attractive therapeutic vehicle 
      for the clinical administration of miRNAs in patients with PDAC.
CI  - Copyright (c) 2018 Elsevier B.V. All rights reserved.
FAU - Ding, Yixuan
AU  - Ding Y
AD  - Department of General Surgery, Xuanwu Hospital, Capital Medical University, 
      Beijing, 100053, China.
FAU - Cao, Feng
AU  - Cao F
AD  - Department of General Surgery, Xuanwu Hospital, Capital Medical University, 
      Beijing, 100053, China.
FAU - Sun, Haichen
AU  - Sun H
AD  - Department of General Surgery, Xuanwu Hospital, Capital Medical University, 
      Beijing, 100053, China.
FAU - Wang, Yecheng
AU  - Wang Y
AD  - Department of General Surgery, Xuanwu Hospital, Capital Medical University, 
      Beijing, 100053, China.
FAU - Liu, Shuang
AU  - Liu S
AD  - Department of General Surgery, Xuanwu Hospital, Capital Medical University, 
      Beijing, 100053, China.
FAU - Wu, Yanchuan
AU  - Wu Y
AD  - Department of Central Laboratory, Xuanwu Hospital, Capital Medical University, 
      Beijing, 100053, China.
FAU - Cui, Qingye
AU  - Cui Q
AD  - Department of General Surgery, Xuanwu Hospital, Capital Medical University, 
      Beijing, 100053, China.
FAU - Mei, WenTong
AU  - Mei W
AD  - Department of General Surgery, Xuanwu Hospital, Capital Medical University, 
      Beijing, 100053, China.
FAU - Li, Fei
AU  - Li F
AD  - Department of General Surgery, Xuanwu Hospital, Capital Medical University, 
      Beijing, 100053, China. Electronic address: lifei20180619@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20181109
PL  - Ireland
TA  - Cancer Lett
JT  - Cancer letters
JID - 7600053
RN  - 0 (Antigens, CD)
RN  - 0 (Apoptosis Regulatory Proteins)
RN  - 0 (CDH1 protein, human)
RN  - 0 (CDH2 protein, human)
RN  - 0 (Cadherins)
RN  - 0 (MIRN145 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (SMAD3 protein, human)
RN  - 0 (Smad3 Protein)
SB  - IM
MH  - Animals
MH  - Antigens, CD/metabolism
MH  - Apoptosis
MH  - Apoptosis Regulatory Proteins/metabolism
MH  - Cadherins/metabolism
MH  - Carcinoma, Pancreatic Ductal/genetics/metabolism/pathology/*therapy
MH  - Cell Cycle Checkpoints
MH  - Cell Line, Tumor
MH  - Cell Movement
MH  - Cell Proliferation
MH  - Exosomes/genetics/metabolism/*transplantation/ultrastructure
MH  - Humans
MH  - Male
MH  - *Mesenchymal Stem Cells/metabolism/ultrastructure
MH  - Mice, Inbred BALB C
MH  - Mice, Nude
MH  - MicroRNAs/genetics/*metabolism
MH  - Neoplasm Invasiveness
MH  - Pancreatic Neoplasms/genetics/metabolism/pathology/*therapy
MH  - Smad3 Protein/metabolism
MH  - Tumor Burden
MH  - Umbilical Cord/*cytology
MH  - Xenograft Model Antitumor Assays
OTO - NOTNLM
OT  - Exosomes
OT  - HucMSC
OT  - MiR-145-5p
OT  - PDAC
OT  - Treatment
EDAT- 2018/11/13 06:00
MHDA- 2019/11/02 06:00
CRDT- 2018/11/13 06:00
PHST- 2018/06/21 00:00 [received]
PHST- 2018/09/14 00:00 [revised]
PHST- 2018/10/25 00:00 [accepted]
PHST- 2018/11/13 06:00 [pubmed]
PHST- 2019/11/02 06:00 [medline]
PHST- 2018/11/13 06:00 [entrez]
AID - S0304-3835(18)30660-8 [pii]
AID - 10.1016/j.canlet.2018.10.039 [doi]
PST - ppublish
SO  - Cancer Lett. 2019 Feb 1;442:351-361. doi: 10.1016/j.canlet.2018.10.039. Epub 2018 
      Nov 9.